Reported about 1 year ago
A new study revealed that Eli Lilly's weight-loss drug tirzepatide, known as Mounjaro, leads to faster and greater weight loss results compared to Novo Nordisk's semaglutide, also known as Ozempic. This discovery is influencing Novo Nordisk's stock valuation as reported by Yahoo Finance Senior Reporter Anjalee Khemlani. The study analyzed over 9,000 patients and highlighted the nuances between the two diabetes drugs and their impact on weight loss, emphasizing the differences in drug dosage and patient characteristics.
Source: YAHOO